Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba Rivera

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infection|December 26, 2022
Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective studyAlaa Atamna, Ili Margalit, Gida Ayada, et al.
Lancet (London, England)|July 9, 2026
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trialFrancesco Cogliati Dezza, Lydia Barrera Pulido, Irene Borreguero Borreguero, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2019
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective StudyTanya Babich, Pontus Naucler, John Karlsson Valik, et al.
Infection|December 26, 2022
Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective studyAlaa Atamna, Ili Margalit, Gida Ayada, et al.
Lancet (London, England)|July 9, 2026
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trialFrancesco Cogliati Dezza, Lydia Barrera Pulido, Irene Borreguero Borreguero, et al.
Pageof 6